R

Read Gene SA
WSE:RDG

Watchlist Manager
Read Gene SA
WSE:RDG
Watchlist
Price: 4.95 PLN -5.53% Market Closed
Market Cap: 58.4m PLN
Have any thoughts about
Read Gene SA?
Write Note

Intrinsic Value

The intrinsic value of one RDG stock under the Base Case scenario is 2.57 PLN. Compared to the current market price of 4.95 PLN, Read Gene SA is Overvalued by 48%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

RDG Intrinsic Value
2.57 PLN
Overvaluation 48%
Intrinsic Value
Price
R
Worst Case
Base Case
Best Case

Valuation Backtest
Read Gene SA

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for RDG cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about RDG?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Read Gene SA

Provide an overview of the primary business activities
of Read Gene SA.

What unique competitive advantages
does Read Gene SA hold over its rivals?

What risks and challenges
does Read Gene SA face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Read Gene SA.

Provide P/S
for Read Gene SA.

Provide P/E
for Read Gene SA.

Provide P/OCF
for Read Gene SA.

Provide P/FCFE
for Read Gene SA.

Provide P/B
for Read Gene SA.

Provide EV/S
for Read Gene SA.

Provide EV/GP
for Read Gene SA.

Provide EV/EBITDA
for Read Gene SA.

Provide EV/EBIT
for Read Gene SA.

Provide EV/OCF
for Read Gene SA.

Provide EV/FCFF
for Read Gene SA.

Provide EV/IC
for Read Gene SA.

Compare the intrinsic valuations
of Read Gene SA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Read Gene SA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Read Gene SA compared to its peers.

Compare the P/E ratios
of Read Gene SA against its peers.

Discuss the investment returns and shareholder value creation
comparing Read Gene SA with its peers.

Analyze the financial leverage
of Read Gene SA compared to its main competitors.

Show all profitability ratios
for Read Gene SA.

Provide ROE
for Read Gene SA.

Provide ROA
for Read Gene SA.

Provide ROIC
for Read Gene SA.

Provide ROCE
for Read Gene SA.

Provide Gross Margin
for Read Gene SA.

Provide Operating Margin
for Read Gene SA.

Provide Net Margin
for Read Gene SA.

Provide FCF Margin
for Read Gene SA.

Show all solvency ratios
for Read Gene SA.

Provide D/E Ratio
for Read Gene SA.

Provide D/A Ratio
for Read Gene SA.

Provide Interest Coverage Ratio
for Read Gene SA.

Provide Altman Z-Score Ratio
for Read Gene SA.

Provide Quick Ratio
for Read Gene SA.

Provide Current Ratio
for Read Gene SA.

Provide Cash Ratio
for Read Gene SA.

What is the historical Revenue growth
over the last 5 years for Read Gene SA?

What is the historical Net Income growth
over the last 5 years for Read Gene SA?

What is the current Free Cash Flow
of Read Gene SA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Read Gene SA.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Read Gene SA

Current Assets 5.2m
Cash & Short-Term Investments 4.4m
Receivables 773.5k
Other Current Assets 16.2k
Non-Current Assets 6.1m
Long-Term Investments 5k
PP&E 5.6m
Intangibles 42k
Other Non-Current Assets 500.9k
Current Liabilities 220.7k
Other Current Liabilities 220.7k
Non-Current Liabilities 9.6m
Other Non-Current Liabilities 9.6m
Efficiency

Earnings Waterfall
Read Gene SA

Revenue
11.6m PLN
Cost of Revenue
-852.5k PLN
Gross Profit
10.8m PLN
Operating Expenses
-11.8m PLN
Operating Income
-979.2k PLN
Other Expenses
-24.1k PLN
Net Income
-1m PLN

Free Cash Flow Analysis
Read Gene SA

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

RDG Profitability Score
Profitability Due Diligence

Read Gene SA's profitability score is 38/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional 3-Years Revenue Growth
Exceptional 1-Year Revenue Growth
Negative Free Cash Flow
38/100
Profitability
Score

Read Gene SA's profitability score is 38/100. The higher the profitability score, the more profitable the company is.

RDG Solvency Score
Solvency Due Diligence

Read Gene SA's solvency score is 60/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Low D/E
Long-Term Solvency
60/100
Solvency
Score

Read Gene SA's solvency score is 60/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

RDG Price Targets Summary
Read Gene SA

There are no price targets for RDG.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for RDG?

Click here to dive deeper.

Dividends

Read Gene SA
does not pay dividends
Shareholder Yield

Current shareholder yield for RDG is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Read Gene SA

Country

Poland

Industry

Biotechnology

Market Cap

58.4m PLN

Dividend Yield

0%

Description

Read-Gene SA engages in the medical research and testing. The company is headquartered in Szczecin, Woj. Zachodniopomorskie. The company went IPO on 2009-02-12. The company is focused on technologies which aim is to detect, prevent and treat malignant tumors. The firm specializes in three fields: chemoprevention, clinical trials and genetic testing. The company offers breast cancer, colon cancer and prostate cancer tests, as well as, medical consultancy, DNA tests and supplements. The firm operates one wholly owned subsidiary, Dieta Antyrakowa Read-Gene Sp. z o.o. Its major shareholder is GEN-PAT-MED Sp. z o.o.

Contact

WOJ. ZACHODNIOPOMORSKIE
Szczecin
ul. Akacjowa 2
+48914334256
www.read-gene.com

IPO

2009-02-12

Employees

-

Officers

See Also

Discover More
What is the Intrinsic Value of one RDG stock?

The intrinsic value of one RDG stock under the Base Case scenario is 2.57 PLN.

Is RDG stock undervalued or overvalued?

Compared to the current market price of 4.95 PLN, Read Gene SA is Overvalued by 48%.

Back to Top